BioSpace News Archive

REGENXBIO Inc. (Nasdaq: RGNX) today announced that data from the RGX-314 clinical trials will be presented in three oral presentations at the American Society of Retina Specialists Annual Meeting taking place in San Antonio, TX, from October 8 to 12, 2021.

Teams at IDEX business units across the United States now have expanded opportunities to volunteer locally as part of a new partnership between Boys & Girls Clubs of America and the IDEX Foundation, the charitable giving extension of IDEX Corporation (NYSE: IEX).

Cybin Inc. is pleased to announce: the addition of Dr. Amir Inamdar as its Chief Medical Officer for its European Operations, the addition of Dr. Geoff Varty as its new Head of Research and Development.

- Dystrophin Restoration of 90% of Wild-Type Levels Observed in the Diaphragm and 78% in the Heart with ~80% Dystrophin-Positive Fibers After a Single Dose in mdx Mouse Model

Bolt Biotherapeutics, Inc. announced that it will be presenting three abstracts at the 2021 Society for Immunotherapy of Cancer’s 36th Annual Meeting, which is being held from Nov. 10-14, both virtually and in person in Washington, D.C.

Roivant Sciences, a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced that it has closed its business combination with Montes Archimedes Acquisition Corp., a special purpose acquisition company, as well as a concurrent PIPE financing.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, to be held both virtually and at the Walter E. Washington Convention Center in Washington, D.C., from November 10 to 14, 2021.

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it will present preclinical data for its anti-VISTA (V-domain Ig suppressor of T cell activation) product candidate, SNS-101, during the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held in Washington, D.C. from November 10 - 14, 2021.

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, successfully hosted the fourth webinar in its virtual investor mini-series.

Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced additional positive interim data from the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics™ for the treatment of recent-onset type 1 diabetes (T1D) (clinical trial identifier: NCT03751007, EudraCT 2017-002871-24).